By running gene and pathway analyses for several smoking behaviours in the Tobacco and Genetics Consortium (TAG) sample of 74 053 individuals, 21 genes and several chains of biological pathways were implicated. Analyses were carried out using the HYbrid Set-based Test (HYST) as implemented in the Knowledge-based mining system for Genome-wide Genetic studies software. Fifteen genes are novel and were not detected with the single nucleotide polymorphism-based approach in the original TAG analysis. For quantity smoked, 14 genes passed the false discovery rate of 0.05 (corrected for multiple testing), with the top association signal located at the IREB2 gene (P = 1.57E-37). Three genomic loci were significantly associated with ever smoked. The top signal is located at the noncoding antisense RNA transcript BDNF-AS (P = 6.25E-07) on 11p14. The SLC25A21 gene (P = 2.09E-08) yielded the top association signal in the analysis of smoking cessation. The 19q13 noncoding RNA locus exceeded the genome-wide significance in the analysis of age at initiation (P = 1.33E-06). Pathways belonging to the Neuronal system pathways, harbouring the nicotinic acetylcholine receptor genes expressing the α (CHRNA 1-9), β (CHRNB 1-4), γ, δ and ε subunits, yielded the smallest P-values in the pathway analysis of the quantity smoked (lowest P = 4.90E-42). Additionally, pathways belonging to 'a subway map of cancer pathways' regulating the cell cycle, mitotic DNA replication, axon growth and synaptic plasticity were found significantly enriched for genetic variants in ever smokers relative to never smokers (lowest P = 1.61E-07). In addition, these pathways were also significantly associated with the quantity smoked (lowest P = 4.28E-17). Our results shed light on one of the world's leading causes of preventable death and open a path to potential therapeutic targets. These results are informative in decoding the biological bases of other disease traits, such as depression and cancers, with which smoking shares genetic vulnerabilities.
INTRODUCTION
Tobacco smoking kills almost six million people each year (World Health Organization, 2015).
1 Despite smoking prevalence decreasing in the past 30 years, there has been a steady increase in the absolute number of smokers, that is, from 721 million in 1980 to 967 million in 2012, owing to accelerated population growth. 2 Aside from environmental influences such as, for example, tobacco availability and social pressure, 3 genetic factors are implicated in all stages of smoking, 4 from experimentation 5 to dependence 5, 6 and cessation. 7 Although genome-wide association studies (GWASs; see Bühler et al., 8 Loukola et al. 9 and Wang et al. 10 for a recent overview) and the meta-analyses conducted by large consortia [11] [12] [13] have provided important insights into the biological bases of smoking, progress has been slow due to the small effects of the single nucleotide polymorphisms (SNPs) and to the multiple testing burden. In genetic studies, the power to detect small effects is linked primarily to sample size (given a fixed alpha level). However, power may also depend on the nature of the genotype-phenotype relation. 14, 15 Most consortia focus initially on individual SNPs showing the strongest evidence for association. The Tobacco and Genetics (TAG) consortium with the largest sample yet of 74 053 individuals identified 130 SNPs (tagging the 15q25 locus) that passed the genome-wide threshold of 5 × 10 − 8 in the quantity smoked analysis. Subsequently, 1025 SNPs that passed the significance threshold of 10 −4 were included in the follow-up SNP-based analyses in the combined TAG, ENGAGE 12 and the Oxford-GlaxoSmithKline 11 sample. We note that the remaining data (summary statistics for up to~2.5 million SNPs in each analysis) have remained largely unexploited. Setbased tests (with a gene or a biological pathway as the unit of analysis) are more powerful than SNP-based tests, 14, 16 as they consider jointly the weak effects of multiple SNPs within a gene or biological pathway. Furthermore, by targeting genomic regions rather than individual SNPs, the number of tests drops from millions to thousands, thus alleviating the multiple testing burden.
Here, we take this next step and mine the publicly available TAG meta-analysis results by conducting pathway analyses and genebased tests. Our aim is to identify biological pathways implicated in smoking behaviours. Our analyses, which are not limited to the most significant loci identified by the TAG meta-analysis, serve to provide additional insights into the biological bases of smoking behaviours.
MATERIALS AND METHODS

The TAG sample
The published TAG meta-analysis results (downloaded from the Psychiatric Genomics Consortium website, https://www.med.unc.edu/pgc/downloads) combined the SNP-based summary statistics of 16 participating cohorts including individuals of European ancestry from Europe and United States. The TAG sample has been described in detail elsewhere (see Table 1 , http://www.nature.com/ng/journal/v42/n5/fig_tab/ng.571_T1.html and the Supplementary Information (http://www.nature.com/ng/journal/v42/n5/ extref/ng.571-S1.pdf) in Tobacco and Genetics Consortium 13 ). In short, the samples were collected mainly between 1970 and 2006. Across the participating studies, the mean age ranged from 39.6 to 72.3 years. In the total combined sample, about 64.37% of the participants were females. Data on smoking status (ever/never smoked regularly) were available for N = 69 409 individuals. Of these, 39 022 individuals declared to have smoked regularly (that is, a regular smoker-according to the Center for Disease Control's (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5844a2. htm) definition-declared to have smoked at least 100 cigarettes during the lifetime). Data on quantity smoked were available in N = 38 181 ever regular smokers, measured either as the average or the maximum number of cigarettes per day (two measures highly correlated over time (40.71) in longitudinally followed samples 17 ). The mean quantity smoked per day varied between 13.1 and 23.4 cigarettes across the participating studies. Data on smoking cessation were available in N = 35 845 individuals. Of these, 20 619 declared to have quit regular smoking (see above for the 'ever regular smoker' definition) at least 1 year prior to the time of the assessment, while the remaining participants were current smokers. Age at initiation, defined as when first smoked or age when started to smoke regularly (the genetic correlation between these two definitions exceeds 0.97, see Consortium TAG 17 ) was observed in N = 22 438 individuals. The average value as observed in the participating samples ranged from 16.4 to 32.2 years of age. Multidimensional scaling, 18 STRUCTURE 19 or EigenSoft principal component analysis 20 were used to address population stratification prior to the study-specific GWAS. Genomic control was further used to correct for potential effects of residual inflation. 13 All the subjects from all studies participating in the TAG consortium provided informed consent.
Statistical analysis
We lifted the SNP positions from HapMap 2 NCBI build 36, Human Genome references 18 to the Human Genome references 19 positions based on dbSNP build 138. Following conversion, there were meta-analysis results available for quantity smoked (2 342 540 SNPs), ever smoking (2 339 474 SNPs), smoking cessation (2 340 171 SNPs) and age at initiation (2 341 140 SNPs). The SNPs passed the TAG consortium's quality criteria (see Supplementary Table 3 (http://www.nature.com/ng/journal/v42/n5/extref/ ng.571-S1.pdf) in Tobacco and Genetics Consortium 13 ). Analyses were carried out using the HYbrid Set-based Test (HYST) as implemented in the Knowledge-based mining system for Genome-wide Genetic studies software. 14, 16 In the HYST approach, the SNPs within the tested set (where the set is a gene or a pathway, consisting of SNPs in linkage disequilibrium (LD)) are firstly partitioned into n weakly correlated blocks on the basis of the LD information. Next, for each of these n LD blocks, a P-value (P block ) is obtained with the Gene-based Association Test that uses the Extended Simes procedure (GATES); 14 that is, for each ith LDblock (i = 1..n), GATES (i) orders ascendingly the P-values (p (1) ..p (m) ) of the m SNPs assigned to that block, (ii) estimates the effective number of independent SNPs m e and m e(j) , among the m SNPs and among the top j SNPs (that is, key SNPs), respectively, by taking account of the LD structure, and (iii) computes the block-based P-value as P block ¼ min combine the n LD block-based P-values as to obtain the overall P-value for the gene/pathway. 16 The LD blocks were inferred 14 based on the 1000 Genomes Haplotypes Phase 3 reference panel ALL (downloaded from ftp:// ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/). We opted for the 1000 Genomes as this is the highest resolution genetic map to date, derived on the basis of a powerful design and utilizing the latent genomic information. 23 Furthermore, the use of this map will facilitate any follow-up analyses in the current GWAS samples as these often include imputed data based on the 1000 Genomes reference panel. Both the gene-based tests and the pathway analyses were conducted genome-wide and utilized the unweighted form of HYST. Variants were assigned to at least one of thẽ 24 100 genes (or within a region extended 5 kb at the 5' and at the 3' end of the gene) based on the UCSC RefGene (hg19) coordinates. Variants missing LD information were discarded. For the pathway analysis, we considered 1320 canonical pathways collected from the Molecular Signature Database 24 (manually curated pathways originating from Reactome, 25 KEGG 26 and BioCarta 27 databases), and restricted the analysis to pathways comprising 10 to 300 genes. We chose a genome-wide significance level of 0.05, and used the Benjamini and Hochberg (BH) method 28 to correct the gene-and pathway-based P-values for multiple testing. The BH method is expected to show better power relative to a Bonferroni correction, which is conservative when the number of tests is large and the tests are correlated.
28,29
RESULTS
The gene-based analyses revealed 21 genes significantly associated with smoking behaviours, including 8 genes in the 15q25 region. Of the 21 genes, 15 genes were not previously reported as significantly associated with any smoking or addiction phenotype in the GWAS catalogue (as of 23 October 2015, see www.genome. gov/gwastudies 30 ), and were not detected with the SNP-based approach in the original TAG analysis. One gene was associated with both quantity smoked and smoking cessation. Results are displayed in Table 1 .
Fourteen genes passed the corrected for multiple testing false discovery rate of 0.05 (ref. 28 ) in the gene-based analysis of quantity smoked (see Table 1a ), with the IREB2 gene on 15q25 yielding the top association (P = 1.57E-37). Three genomic loci exceeded genome-wide significance in the ever smoking analysis (Table 1b) . The top signal was yielded by the noncoding antisense RNA transcript BDNF-AS (P = 6.25E-07) on 11p14. Note also that the CDC27 gene, harbouring the rs16941640 SNP with the lowest P-value in the initial TAG analysis (P = 2.2E-07), achieved significance in our gene-based analysis (P = 3.04E-06). Two genes were significantly associated with smoking cessation (see Table 1c ), with the SLC25A21 gene on 14q13 yielding the lowest P-value (P = 2.09E--08). The gene-based tests revealed the noncoding RNA MIR1323-MIR512-1-MIR512-2 locus on 19q13 as significantly associated with age at initiation (P = 1.33E-06; Table 1d ). Note that no individual SNP reached significance in the original TAG analysis of age at initiation. We refer to the Supplementary Table S1 for details on gene  functions and to the Supplementary Tables S2-S5 for details on SNPs assigned to genes.
Results for the statistically significant pathways are summarized in Table 2 . Details on genes assigned to the pathways are given in Supplementary Tables S6 and S7 . The reported P-values passed the (corrected for multiple testing) false discovery rate of 0.05.
As indicated in Table 2 , the pathways reaching statistical significance form chains of pathways, rather than being isolated hits spread across the genome. We identified several chains of biological pathways significantly associated with the quantity smoked (see Table 2a ). Highly enriched are the neuronal system pathways harbouring the nicotinic acetylcholine receptor genes expressing the α (CHRNA 1-9), β (CHRNB 1-4), γ, δ and ε subunits; the three strongest signals were yielded by the highly calciumpermeable postsynaptic nicotinic acetylcholine receptors pathway (P = 4.90E-42), the acetylcholine binding and downstream events (P = 3.11E-41) and the presynaptic nicotinic acetylcholine receptors (P = 8.42E-32) pathway. Note that some of the genes are assigned to more than one pathway, indicating that they have roles in multiple biological processes underlying the smoking behaviours. For instance, the CHRNA3/5 gene cluster on 15q25 (see Supplementary Table S6 ) was assigned to all three top pathways in the quantity smoked analysis. Excluding this gene cluster from the analysis showed that while the highly calciumpermeable postsynaptic nicotinic acetylcholine receptors and the acetylcholine binding and downstream events pathways remained highly significant (that is, P = 1.27E-22 and P = 1.18E-21, respectively), the P-value for the presynaptic nicotinic acetylcholine receptors dropped to P = 1.10E-04, suggesting that the association with this pathway was driven in part by the inclusion of these well-established candidate loci.
Furthermore, the quantity smoked was statistically associated with pathways regulating the immune system (with the cross presentation of soluble exogenous antigens endosomes pathway yielding the strongest association; P = 4.38E-17), metabolism (where the regulation of ornithine decarboxylase ODC pathway yielded the strongest signal; P = 6.71E-16), signal transduction (with the signalling by WNT pathway exceeding the significance threshold; P = 1.18E-17) and asthma pathways (P = 3.10E-04). In addition, particularly enriched are the cell cycle checkpoints pathways governing the transition of the new cell from one stage to another and the programmed cell death, with strong association signals coming from the P53-dependent G1 DNA damage response pathway (P = 7.24E-20) and from the pathway regulating apoptosis (P = 1.84E-09).
Note that the cell cycle pathways (displayed in italics in Table 2 ) are also implicated in ever smoking. These pathways relate to the Anaphase-Promoting Complex/Cyclosome-mediated degradation of Cdc20 and other APC/C Cdh1 -targeted proteins. Although none of these pathways is associated with both smoking phenotypes, they are inter-connected, forming chains of pathways governing different stages of cell division. Especially enriched in ever smokers is the conversion from APC Cdc20 to APC Cdh1 in late anaphase pathway (P = 1.61E-07), while in the quantity smoked analysis, enrichment signals come from the autodegradation of Cdh1 by Cdh1:APC/C pathway (P = 4.28E-17) and from the APC/ C Cdh1 -mediated degradation of Cdc20 and other APC/C Cdh1 -targeted proteins in late mitosis/early G1 pathway (P = 1.99E-16). We identified no significant pathways for age at initiation or smoking cessation.
DISCUSSION
We have extended the original TAG analysis and the previous work that has implicated SNPs and genes in smoking behaviours. Our results illustrate the utility of secondary analyses of published, publicly available datasets, and demonstrate that following-up the SNP-based tests by gene and pathway analyses can lead to considerable gains in statistical power and can yield important insights into the biological mechanisms underlying the trait of interest. The gene-based analysis revealed 21 genes implicated in smoking behaviours. Of these, 15 are novel and were missed with the SNP-based approach in the original TAG analysis. Aside from the known cluster of genes (IREB2-CHRNA3-CHRNA5-CHRNB4-HYKK-PSMA4), we identified a cluster of three loci on the same chromosome 15 (ADAMTS7, MORF4L1 and LOC646938, P = 4.48E--17, 1.18E-06 and 1.66E-05, respectively). The ADAMTS7-MORF4L1 locus has been previously associated with, for example, coronary artery disease 31 for which smoking is a known risk factor. On the basis of a joint analysis, SNPs within ADAMTS7 and MORF4L1 were recently listed as candidate signals for smoking behaviour independent of those yielded by the known loci rs16969968 or rs588765 in CHRNA5. 32 Regarding the two significant associations on chromosome 1 (that is, SHISA4 and IPO9 genes, P = 1.52E-06 and 5.45E-06, respectively), we note that neither of these have been previously associated with any addiction behaviour.
We also located statistically significant signal coming from the known HLA locus on chromosome 6, result suggesting a link between smoking and the immune system. Loci in the HLA region have been previously implicated in, for example, schizophrenia, 33 with which smoking dependence shares genetic vulnerabilities. Three genomic loci were significantly associated with ever smoking. The top signal came from the noncoding antisense RNA transcript BDNF-AS locus (P = 6.25E-07) on chromosome 11. BDNF-AS downregulates the BDNF gene, 34 which in turn has a key role in regulating neuronal growth and synaptic plasticity. 34, 35 The BDNF gene did not reach genome-wide significance in our genebased analysis (P = 1.3E-04), result indicating that the eight significant SNPs reported in the combined TAG analysis were tagging better the overlapping noncoding RNA BDNF-AS locus (see Supplementary Figures  36 for LD information) .
Two genes exceeded genome-wide significance with smoking cessation: the SLC25A21 gene on chromosome 14 and with the SEMA6D gene on chromosome 15 (P = 1.64E-06). The role these genes have in smoking cessation and their potential as therapeutic targets has yet to be elucidated. SEMA6D expression levels were recently shown to significantly predict survival in patients with breast cancer; 37 also, the gene was listed among potential targets in cancer therapy owing to its role in regulation of the immune response. 38 The SLC25A21 gene was previously proposed as a plausible candidate for smoking cessation 39 and current smoking. 40 Notice that the SLC25A21 gene was the only one significantly associated with two smoking behaviours, namely with quantity smoked (P = 1.41E-05) and smoking cessation (P = 2.09E-08), result consistent with the large genetic correlation between the two smoking behaviours (r g = − 0.62; Po0.001) 41 observed in this sample. The 19q13 MIR1323-MIR512-1-MIR512-2 noncoding RNA locus exceeded genome-wide significance in the age at initiation analysis (P = 1.33E-06). Importantly, loci in the 19q13 region were previously implicated in quantity smoked by the TAG Consortium in their combined analysis and also by the ENGAGE 11 analysis and, recently, by Loukola et al.; 42 the region has been proposed as a plausible candidate for further investigation in relation to smoking quantity given its role in nicotine metabolism (see, for example, Tobacco and Genetics Consortium 13 ). We now add age at initiation to the list of smoking phenotypes to be further investigated in relation to this biologically plausible region.
By extending the tested genomic region from genes to pathways-where a pathway is a 'meta-gene' comprising multiple genes having the same biological function-we identified chains of pathways statistically associated with ever smoking and quantity smoked (see Supplementary Figures  43 ) . The strongest association signal in the quantity smoked analysis was yielded by the highly calcium-permeable postsynaptic nicotinic acetylcholine receptors pathway (P = 4.90E-42) harbouring the nicotinic acetylcholine receptors. The results are consistent with the hypothesis that mechanisms underlying smoking dependence involve the mesocorticolimbic dopamine system. 10, 44 In short, as Benowitz 44 described, the biological mechanisms underlying nicotine addiction involve nicotine binding to the nicotinic acetylcholine receptors which, in turn, release several neurotransmitters (dopamine, glutamate and γ-aminobutyric acid) in regions of the brain known to be involved in the perception of pleasure and reward (that is, in the ventral tegmental area and the shell of the nucleus acumbens). Following repeated exposure, the nicotinic acetylcholine receptors adapt to nicotine and become unresponsive. It is hypothesized that the reactivation of these closed receptors following abstinence/cessation gives rise to symptoms of craving and withdrawal which, in turn, reinforce continuing smoking/relapse. We implicated in quantity smoked and ever smoking pathways relating to the Anaphase-Promoting Complex/ Cyclosome-mediated degradation of Cdc20 and other APC/C Cdh1 -targeted proteins. Although none of these pathways was associated with both smoking phenotypes, they are interconnected, forming chains of pathways governing different stages of cell division. These pathways control not only the mitotic regulators of DNA replication (that is, APC Cdc20 ) but also axon growth and synaptic plasticity (that is, APC Cdh1 ); 45 hence, our results lend support to the idea that neuronal plasticity and learning have a paramount role in the development of nicotine addiction. 44 Furthermore, because the cell cycle pathways are known to belong to 'a subway map of cancer pathways' 46 given their role in cancer development (a disease of unregulated cell proliferation), our results suggest that some of the same biological mechanisms underlie both smoking and cancer, as first conjectured by Fisher: 47 ' […] cigarette smoking and lung cancer, though not mutually causative, are both influenced by a common cause, in this case the individual genotype'. While the mediation study by VanderWeele et al. 48 demonstrated that variants at the 15q25 locus have a direct effect on both smoking and lung cancer, it will be of interest to determine whether their conclusion generalizes at the pathway level as suggested by the present results. If that is the case, the novel cancer therapies targeting the cell cycle regulators 49 might yield clues of particular importance for the development of efficient smoking cessation therapy.
As detailed in the Supplementary Tables S6 and S7 , our results provide clues on many other genes sharing the same pathways, genes that act in concert to give rise to individual differences in smoking behaviours. The genes and pathways reported herein worth further investigation in relation to other addiction phenotypes and disease traits such as depression, 50 schizophrenia 51 or cancers, 48, 52 with which smoking shares genetic factors. 53 Of the existing algorithms, [54] [55] [56] [57] we chose HYST to conduct the pathway analyses because: (i) it has adequate control of the type I error rate, (ii) good power (that is, it is at least as powerful as-and in some circumstances-more powerful than alternative set-based tests 14, 16 ), (iii) it is computationally efficient (that is, it does not rely on permutations/simulations to account for LD between the SNPs when computing the P-values), (iv) it exploits all the available information (that is, the SNP P-values and their LD structure) to compute the pathway P-value, and thus does not require arbitrarily chosen P-value thresholds for selecting the list of input genes, and (v) importantly, it uses up to date annotation information on variants, genes and pathways from bioinformatics databases. Yet, despite the differences in terms of assumptions and the algorithm's power, we note that in large samples as the one we used, results obtained based on alternative pathwaybased approaches converge 56 (see also Supplementary Tables S8  and S9 for results obtained using an alternative overrepresentation test as implemented in Reactome 25 ). In view of this and to avoid the loss in power associated with increasing the number of tests, we limited our analysis strategy to HYST.
As it is based on gene-level statistics obtained in a meta-analytic sample, our study overcomes some limitations of previous exploratory pathway studies 10, 53, 58 such as, for example, the literature selection bias, the bias arising from the use of incongruent analysis protocols or the heterogeneity problem 59, 60 arising from incongruent definition, assessment and/or distributional properties of the phenotype in question across the selected studies. More importantly, we (and, previously, Vink et al. 40 ) use a hypothesis-free/unbiased genome-wide approach in deriving the list of input genes to be included in the pathway analyses. In doing so, our study surmounts the 'circularity' bias of previous pathway studies 10,58 built on lists of input genes mostly derived from published confirmatory/candidate gene studies. Furthermore, by being based on HYST 14 -which uses the scaled chisquare test to combine the LD-block-based P-values calculated with the GATES procedure-the study presented herein overcomes the limitations of other pathway-based tests such as, for example, the overrepresentation tests that do not take into account the correlation structure among the genes within pathways and among the SNPs within genes, or require arbitrary P-value thresholds to select the list of input genes.
We note the following limitations of the current study. First, the analyses were limited to the main effects of the genetic variants on smoking behaviours. It is possible that the aggregate effect of genetic variants within the significant pathways on smoking behaviours depends on exposure to environmental risk factors. Such gene-environment interaction remains to be studied, but will become feasible in the coming years, as the requisite large samples with raw genotype data and harmonized (across cohorts) measures of environmental exposures become available. 61 Second, HYST identified several genes on chromosome 15q25 as significantly associated with the quantity smoked. Aside from the known cluster of genes (IREB2-CHRNA3-CHRNA5-CHRNB4-HYKK-PSMA4), we identified a cluster of three genes on the same chromosome 15 (ADAMTS7, MORF4L1 and LOC646938, P = 4.48E-17, 1.18E-06 and 1.66E-05, respectively). We note that based on a joint-analysis, SNPs within ADAMTS7 and MORF4L1 were recently listed as candidate signals for smoking behaviour independent of those yielded by the known loci rs16969968 or rs588765 in CHRNA5. 32 Further zooming into this genomic region through SNP conditional analysis and molecular experiments is desirable to completely disentangle which of these signals are independent, as well as for gene function validation. 16 Third, this study is based on summary statistics obtained by the 16 TAG participating groups in GWASs, which controlled for the effects of age and sex. It is a limitation of the present study that we could not consider other covariates, which may have an effect on the phenotypes of interests or on the genetic effects on the present phenotypes.
Possible covariates include cohort, the availability of tobacco and social pressure to start/quit smoking. Finally, we emphasize that the present results are based on a sample limited to individuals of European ancestry. Whether the biological pathway and genes identified here will replicate in populations of other ancestries remains to be established.
In conclusion, by running gene and pathway analyses in the TAG sample, 21 genes and several chains of biological pathways were implicated. Using the largest sample amassed yet in a GWAS of smoking, we found that aside from the nicotinic acetylcholine receptors-known for the rewarding role they have in nicotine dependence-the cell cycle regulators are possible targets in smoking cessation therapy. Our results shed light on one of the world's leading causes of preventable death and open a path to potential targets for therapeutics. These results are informative in decoding the biological bases of the addiction phenotypes and disease traits such as schizophrenia, depression and cancers with which smoking shares risk loci and biological pathways.
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